GPR34 and neoplasm: In both human tumors and preclinical models, elevated expression of ABHD16A (LysoPS synthase that converts cell-surface phosphatidylserine into LysoPS) or GPR34 was inversely correlated with ILC1 activity, highlighting a novel metabolic checkpoint that could be applied therapeutically to unlock ILC1-mediated tumor suppression (Figure 1E) (188, 189).